Neos Therapeutics (NEOS) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

Other equities analysts have also issued reports about the stock. Cowen restated a buy rating on shares of Neos Therapeutics in a research report on Thursday, October 26th. Cantor Fitzgerald set a $20.00 price objective on shares of Neos Therapeutics and gave the company a buy rating in a research report on Thursday, October 26th. Wells Fargo & Co set a $14.00 price objective on shares of Neos Therapeutics and gave the company a buy rating in a research report on Wednesday, October 18th. Finally, Zacks Investment Research upgraded shares of Neos Therapeutics from a hold rating to a buy rating and set a $9.00 price objective for the company in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $14.00.

Neos Therapeutics (NASDAQ:NEOS) opened at $10.20 on Wednesday. The company has a debt-to-equity ratio of 4.01, a quick ratio of 2.14 and a current ratio of 2.42. Neos Therapeutics has a 12 month low of $4.85 and a 12 month high of $13.15.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.22. Neos Therapeutics had a negative net margin of 339.52% and a negative return on equity of 551.26%. The company had revenue of $6.70 million during the quarter. research analysts forecast that Neos Therapeutics will post -2.87 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in NEOS. Russell Investments Group Ltd. lifted its position in Neos Therapeutics by 167.9% during the second quarter. Russell Investments Group Ltd. now owns 270,020 shares of the company’s stock valued at $1,971,000 after purchasing an additional 169,237 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Neos Therapeutics by 103.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 43,700 shares of the company’s stock valued at $320,000 after purchasing an additional 22,200 shares during the last quarter. Rhumbline Advisers lifted its position in Neos Therapeutics by 13.6% during the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after purchasing an additional 2,441 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in Neos Therapeutics during the second quarter valued at approximately $102,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Neos Therapeutics during the second quarter valued at approximately $110,000. Institutional investors own 45.75% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://transcriptdaily.com/2017/12/31/neos-therapeutics-neos-raised-to-hold-at-bidaskclub.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply